CliffBio
small molecule

AMVUTTRA

VUTRISIRAN SODIUM

Loss of exclusivityJuly 2036latest FDA-listed patent expiry
CompanyAlnylam Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameAMVUTTRA
Active ingredientVUTRISIRAN SODIUM
StrengthEQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalJune 2022
Marketing statusRX

Listed patents

PatentExpiresType
11286486July 2036substance, product
10208307July 2036substance, product
12049628July 2036substance, product
10683501July 2036substance, product
10612024August 2035substance, product
11401517August 2035substance, product
10570391November 2032substance, product
9399775November 2032substance, product
8106022December 2029substance, product
10806791December 2028substance
9370581December 2028substance, product
8828956December 2028substance, product
10131907August 2028substance, product

Regulatory exclusivity

CodeExpires
ODE-527March 2032
ODE-212June 2029
I-964March 2028
NCEJune 2027

More from Alnylam Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

AMVUTTRA patent cliff — loss of exclusivity July 2036 | CliffBio